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course, developing slowly over many years, and when there
is a lack of overt hormonal symptoms they may have been
present for a considerable period of time before diagnosis.
Therefore, NETs are commonly found with metastatic disease
at diagnosis, especially in the most common variant small-
intestinal NETs (SI-NETs). Surgical treatment of NETs varies
somewhat according to site of origin and extent of disease.
Surgical treatment of liver metastases is generally indicated
if there are less than about five tumours, if they are confined
to one lobe or in the case of large tumours as a debulking op-
tion to reduce hormonal release.
However, there are several alternative options. First of all,
stabilisation of disease is important, usually achieved by offer-
ing biotherapy (SI-NETs) or chemotherapy (pancreatic or
pulmonary NETs). In addition, treatment with 177luthetium-la-
belled somatostatin analogues in tumours expressing somato-
statin receptors has emerged as a possible option for initial
treatment. After stabilisation of the disease, or even reduction
of the tumour burden, often achieved by these treatments,
surgery may become an option. A likewise targeted metasta-
sis-directed therapy is ablation by radiofrequency (RFA), micro-
wave (MW) or recently also irreversible electroporation (IRE).
Another available option is hepatic artery embolisation.
Therefore, surgical management of liver metastases may
be offered at different stages of the disease. In some cases
the goal is total eradication of metastases from the liver, in
other cases as anothermethod to keep the disease ‘under con-
trol’ or as a debulking procedure to reduce hormonal levels.
RFA or MW for SI-NETs has been evaluated and found to be
safe, to reduce hormonal levels, and to reduce symptoms
such as diarrhoea and abdominal pain. However, there seems
to be no improvement on survival, although no randomised
trial to test this has yet been conducted.
Surgery has classically involved standard resections such
as segmentectomies or hemihepatectomy, but recently a
more local approach has been utilised as an alternative to
the likewise local RFA or MW. No studies have compared liver
surgery for NETs with the alternatives, but studies havedemonstrated the safety of – and clear benefit as a result of
– surgery as a debulking procedure.
Studies in SI-NET have shown that the recurrence rate of
liver metastases is very high. In careful microscopic evalua-
tions of resected liver specimens it is clear that there are al-
most always several previously unrecognised metastases
present, perhaps indicating the impossible goal of reaching
microscopic R0.
In pancreatic NETs the situation may be different. Unless
diffusely spread, R0 may be achieved in the liver, and if com-
bined with proper chemotherapy an impressively stable dis-
ease may be achieved compared with previously.
Liver transplantation has been advocated in patients with
pancreatic NETs, Ki67 < 10% and lack of extrahepatic disease.
In practice, however, this situation is rather rare, since
lymph-node and skeletal metastases are often present,
nowadays visualised with the more sensitive tools of today
(Ga-DOTATOC/TATE PET). For SI-NET, liver transplant would be
theoretically preferable considering the high rate of unknown
liver metastases, but the survival for such patients has a
median of >20 years, raising doubts about whether liver trans-
plant is anoption. Indeed, themetastases inSI-NETs commonly
also occur at other sites than in the liver – but may still be con-
trolled with the appropriate biotherapy treatment, as well as
with 177Lu in certain cases. Indeed, there are reports of very suc-
cessful liver transplant case series, but also cases with recur-
rence of disease in the new liver associatedwith short survival.
Overall, no comparative or randomised studies are avail-
able to support any evidence-based recommendations. There
are several patient case series describing long survival and
improvement of symptoms after liver surgery, but these are
of small value because of lack of comparisons. On the other
hand, liver surgery or ablative procedures may still be chosen
by the individual patient when offered, as a variant of per-
sonalised medical care.
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